To prohibit the National Institutes of Health and any other Federal agency from funding gain-of-function research conducted in China.
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Senate amendment proposed (on the floor): Amendment SA 2003 proposed by Senator Cantwell for Senator Paul to Amendment SA 1502.
May 25, 2021
View full timeline
Senate amendment proposed (on the floor): Amendment SA 2003 proposed by Senator Cantwell for Senator Paul to Amendment SA 1502.
May 25, 2021
Senate amendment agreed to: Amendment SA 2003 agreed to in Senate by Voice Vote.
May 25, 2021
Senate amendment submitted
May 25, 2021
Amendment SA 2003 proposed by Senator Cantwell for Senator Paul to Amendment SA 1502. (consideration: CR S3408-3409; text: CR S3402) To prohibit the National Institutes of Health and any other Federal agency from funding gain-of-function research conducted in China.
May 25, 2021
Amendment SA 2003 agreed to in Senate by Voice Vote.
May 25, 2021
Text
Submitted
SA 2003. Mr. PAUL (for himself, Mr. Johnson, Mr. Tuberville, Mr. Marshall, Mr. Braun, and Mr. Tillis) proposed an amendment to amendment SA 1502 proposed by Mr. Schumer to the bill S. 1260, to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes; as follows: At the appropriate place, insert the following: SEC. __. PROHIBITION ON FUNDING FOR GAIN-OF-FUNCTION RESEARCH CONDUCTED IN CHINA. (a) In General.--No funds made available to any Federal agency, including the National Institutes of Health, may be used to conduct gain-of-function research in China. (b) Definition of Gain-of-function Research.--In this section, the term ``gain-of-function research'' means any research project that may be reasonably anticipated to confer attributes to influenza, MERS, or SARS viruses such that the virus would have enhanced pathogenicity or transmissibility in mammals. ______